IN8bio presented new biological correlative data from the ongoing Phase 1 clinical trial of INB-200 targeting newly diagnosed glioblastoma multiforme in a poster presentation at the Society for Immunotherapy of Cancer’s, SITC, 38th Annual Meeting. “Gamma-delta T cells are important in immune responses and their high levels are known to correlate with improved survival outcomes. Efficient immune reconstitution is pivotal for favorable outcomes in cancer patients. This new analysis sheds light on how our DeltEx DRI gamma-delta T cell approach may induce durable persistence and immune responses,” said William Ho, Co-founder and CEO. “These important insights will help inform the ongoing development of our DeltEx DRI therapies across a variety of solid and hematological tumors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INAB:
- IN8bio presents ‘positive’ data from iPSC platform at SITC
- IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
- IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
- IN8bio completes Phase 1 INB-100 enrollment, begins Phase 2 INB-400 enrollment
- IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
